Moleculin Biotech Inc (NASDAQ:MBRX)

3.93
Delayed Data
As of Jun 14
 +0.07 / +1.81%
Today’s Change
3.12
Today|||52-Week Range
9.30
-17.83%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$109.7M

Company Description

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML); and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Contact Information

Moleculin Biotech, Inc.
5300 Memorial Drive
Houston Texas 77007
P:(713) 300-5160
Investor Relations:

Employees

Shareholders

Other institutional5.04%
Mutual fund holders2.56%
Individual stakeholders0.00%

Top Executives

Walter V. KlempChairman, President & Chief Executive Officer
Jonathan P. FosterChief Financial Officer & Executive Vice President
Robert ShepardChief Medical Officer-Annamycin
Donald H. PickerChief Science Officer
Sandra Leta SilbermanChief Medical Officer-New Products